Institut de Recherche Interdisciplinaire (IRIBHM), Université Libre de Bruxelles, Campus Erasme, Brussels, Belgium.
Bioessays. 2012 Aug;34(8):634-42. doi: 10.1002/bies.201100195. Epub 2012 May 29.
Phosphoinositide (PI) phosphatases such as the SH2 domain-containing inositol 5-phosphatases 1/2 (SHIP1 and 2) are important signalling enzymes in human physiopathology. SHIP1/2 interact with a large number of immune and growth factor receptors. Tyrosine phosphorylation of SHIP1/2 has been considered to be the determining regulatory modification. However, here we present a hypothesis, based on recent key publications, highlighting the determining role of Ser/Thr phosphorylation in regulating several key properties of SHIP1/2. Since a subunit of the Ser/Thr phosphatase PP2A has been shown to interact with SHIP2, a putative mechanism for reversing SHIP2 Ser/Thr phosphorylation can be anticipated. PI phosphatases are potential target molecules in human diseases, particularly, but not exclusively, in cancer and diabetes. Therefore, this novel regulatory mechanism deserves further attention in the hunt for discovering novel or complementary therapeutic strategies. This mechanism may be more broadly involved in regulating PI signalling in the case of synaptojanin1 or the phosphatase, tensin homolog, deleted on chromosome TEN.
磷酸肌醇(PI)磷酸酶,如含 SH2 结构域的肌醇 5-磷酸酶 1/2(SHIP1 和 2),是人类生理病理学中的重要信号酶。SHIP1/2 与大量免疫和生长因子受体相互作用。SHIP1/2 的酪氨酸磷酸化被认为是决定调节修饰。然而,在这里,我们基于最近的关键出版物提出了一个假设,强调了 Ser/Thr 磷酸化在调节 SHIP1/2 的几个关键特性方面的决定作用。由于 Ser/Thr 磷酸酶 PP2A 的一个亚基已被证明与 SHIP2 相互作用,因此可以预期存在一种逆转 SHIP2 Ser/Thr 磷酸化的假定机制。PI 磷酸酶是人类疾病的潜在靶分子,特别是但不限于癌症和糖尿病。因此,在寻找新的或补充的治疗策略时,这种新的调节机制值得进一步关注。在突触结合蛋白 1 或磷酸酶,张力蛋白同源物,染色体 TEN 缺失的情况下,这种机制可能更广泛地参与调节 PI 信号。